pyrazines has been researched along with Tongue Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arasaki, A; Kawabata-Iwakawa, R; Kina, S; Kinjo, T; Miyamoto, S; Sunakawa, H | 1 |
| Lorch, JH; Schmoll, HJ; Thomas, TO | 1 |
2 other study(ies) available for pyrazines and Tongue Neoplasms
| Article | Year |
|---|---|
A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Synergism; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Pyrazines; Pyridines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Tongue Neoplasms; Wnt Signaling Pathway; Young Adult | 2021 |
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
Topics: Adherens Junctions; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Movement; Desmoglein 2; Desmoplakins; Desmosomal Cadherins; Drug Synergism; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Pyrazines; Tongue Neoplasms | 2007 |